Results 261 to 270 of about 723,030 (329)

Time, the final frontier

open access: yesMolecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain   +3 more
wiley   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

open access: yesMolecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson   +11 more
wiley   +1 more source

Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis

open access: yesMolecular Oncology, EarlyView.
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger   +2 more
wiley   +1 more source

Analysis of the genetic variability and immunological properties of the NlpB antigen, a novel protein identified in Neisseria meningitidis

open access: yesBiotecnología Aplicada
Maité Delgado   +15 more
doaj  

Genetic engineering of Starmerella bombicola for the production of cellobiose lipids [PDF]

open access: yes, 2013
D'Hondt, Yaïka   +3 more
core  

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu   +11 more
wiley   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

open access: yesMolecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez   +17 more
wiley   +1 more source

Understanding and measuring mechanical signals in the tumor stroma

open access: yesFEBS Open Bio, EarlyView.
This review discusses cancer‐associated fibroblast subtypes and their functions, particularly in relation to extracellular matrix production, as well as the development of 3D models to study tumor stroma mechanics in vitro. Several quantitative techniques to measure tissue mechanical properties are also described, to emphasize the diagnostic and ...
Fàtima de la Jara Ortiz   +3 more
wiley   +1 more source

Expression and purification of E140 protein antigen fragments of Plasmodium vivax and Plasmodium berghei for serological assays

open access: yesFEBS Open Bio, EarlyView.
We provide a step‐by‐step guide for producing E140 antigen fragments from Plasmodium berghei (Pb1) and Plasmodium vivax (Pv1). Pb1/Pv1 are expressed in E. coli, solubilized by freeze–thawing, refolded by slow dilution, purified by affinity chromatography (IMAC), then concentrated and subjected to quality control.
Rodolfo Ferreira Marques   +5 more
wiley   +1 more source

HDAC4 regulates apoptosis in Acan‐CreERT2;HDAC4d/d mice with osteoarthritis by downregulating ATF4

open access: yesFEBS Open Bio, EarlyView.
Using the AcanCreERT2;HDAC4fl/fl genetic mouse model, we further investigated the role of histone deacetylase 4 (HDAC4) in chondrocyte apoptosis. We found that knocking down HDAC4 may be associated with chondrocyte apoptosis by upregulating the activating transcription factor 4 (ATF4)/CAAT/enhancer binding protein homologous (CHOP) signaling pathway ...
Jingrui Huang   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy